Menu
A Message from Robert F. Kennedy Jr. - Chairman on Leave
October 21, 2022

COVID and Kids: Is My Child At Risk?

From

 

Kids

Acknowledgement and support for the injured young holds a special place for all of us. After rolling up their sleeves and doing what they were asked, they’re now ill with life-altering injuries with nowhere to turn and no one to help.

COVID and Kids: Is my child at risk?   –   Natural Immunity   –   Risk vs. Benefit   –   Stories   –   Science

COVID and Kids: Is My Child At Risk?

On October 20, 2022, the Center for Disease Control claimed the benefits outweigh the risks and voted YES to approve to add the COVID-19 vaccines to the children’s immunization schedule.

No pharmaceutical product is 100% safe. There are risks with all drugs and vaccines. The important point to note is that if your child is harmed by the COVID vaccine there is no support for your child. The drug companies are not liable, the government is not liable if something goes wrong.

What is the risk-benefit profile for these vaccines? We break this down below.

1. Natural Immunity

The CDC has recognized that natural immunity is a valid way of protection against COVID-19.

“Natural immunity is acquired from exposure to the disease organism through infection with the actual disease… Either way, if an immune person comes into contact with that disease in the future, their immune system will recognize it and immediately produce the antibodies needed to fight it. Active immunity is long-lasting, and sometimes life-long.

Source: CDC.gov

Source: CDC.gov

86.3% of kids in the U.S. have already had COVID-19

What is a responsible approach to help the remaining 13% achieve immunity?

2. Risk vs. Benefit

32 children died aged 0-17 from COVID-19 in 2022. Source: CDC data tracker

26 children died aged 0-17 from the COVID-19 vaccine in 2022. Source: CDC VAERS system

Upon further analysis, we believe the total child deaths reported in VAERS to be up to 400+. Further explanation can be found at bottom of the page.

While over 86% of the child population in the U.S. now have natural immunity, only 16-29% have been vaccinated. Yet COVID mortality for this age group remains statistically at 0.00%. Source: FAIR Health White Paper: Johns Hopkins University & West Health Institute

What is the true need for a COVID vaccine for a population already immune, in the face of known and unknown harms of COVID vaccination?

3. What Happens if My Child is Harmed?

The U.S. government insists there are many programs set in place to identify and help those who are harmed after COVID vaccination, i.e., VAERS, CICP. However, these programs are broken. VAERS is not identifying safety signals, nor has a single COVID vaccine-injured person received financial support through any federal compensation program. In addition, medical teams have not been educated on these reactions.

If your child is harmed YOU ARE ON YOUR OWN.

Stories: First-Hand Testimonies of the Injured Young

4. What Does the Science Say?

Sufficient clinical trials have not been conducted. The FDA made an unprecedented move to authorize the most recent bivalent booster based on a study of mice, zero humans. Source: NPR

Are there adverse events involving kids? YES. There are over 49,000 reports of adverse events in VAERS with kids, including death.

React19’s stance is that the public must be made aware of the potential risks to their child so they can make an informed decision.

** 0 Claims paid as of October 2022. Including myocarditis and fatalities in all age groups. Source: HRSA.gov

GBS in a 14yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34717201/

COVID-19 vaccine induced MOGAD transverse myelitis in a 15yoM: https://pubmed.ncbi.nlm.nih.gov/35626851/

Polyneuritis cranialis, a rare GBS variant, associated with Pfizer in a 16yoF: https://pubmed.ncbi.nlm.nih.gov/35062795/

Zoster Meningitis in a 12yoM following 1st dose Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/35680126/

Aseptic meningitis, mucocutaneous lesions, and arthritis after Pfizer in a 15yoM: https://pubmed.ncbi.nlm.nih.gov/35214783/

18yoM with aseptic meningitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34711784/

15yo with Pfizer induced encephalopathy, myocarditis, and thrombocytopenia with excellent response to methylprednisolone: https://pubmed.ncbi.nlm.nih.gov/35561428/

First episode of psychosis in 18yoF following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35091388/

2 cases of fetal tachycardia following Pfizer vaccination during pregnancy: https://pubmed.ncbi.nlm.nih.gov/36248062/

Cardiovascular manifestation of the Pfizer covid-19 vaccine in adolescentshttps://pubmed.ncbi.nlm.nih.gov/36006288/

Perimyocarditis in teenshttps://pubmed.ncbi.nlm.nih.gov/34077949/

Vaccination associated myocarditis in adolescentshttps://pubmed.ncbi.nlm.nih.gov/34389692/

mRNA vaccination and myocarditis in adolescentshttps://pubmed.ncbi.nlm.nih.gov/34393110/

STEMI mimic: focal myocarditis in an adolescent patient after mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34756746/

Myocarditis following 2nd dose of Pfizer in 2 adolescent brothers: https://pubmed.ncbi.nlm.nih.gov/35455360/

Myocarditis in a 13yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35475062/

Myocarditis in a 8yoM following Pfizer 2nd dose: https://pubmed.ncbi.nlm.nih.gov/35892184/

Acute perimyocarditis in a 14yoM following Pfizer booster: https://pubmed.ncbi.nlm.nih.gov/36002252/

Myocarditis in 13yoM monochorionic diamniotic twins following 2nd dose of Pfizer:https://pubmed.ncbi.nlm.nih.gov/36008643/

Myocarditis in a 14yoM: following covid-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35938599/

Myocarditis in a 15yo following Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369878/

Myocarditis in a 15yoM following 2nd dose of Pfizer with late gadolinium enhancement on cardiac MRI persisting over acute phase: https://pubmed.ncbi.nlm.nih.gov/36074060/

Myopericarditis in a 16yo following vaccination: https://pubmed.ncbi.nlm.nih.gov/34133825/

Myocarditis in a 16yoM with myocarditis and ventricular tachycardia following Pfizer 2nd dose, a 5.5 month follow-up:https://pubmed.ncbi.nlm.nih.gov/35949160/

Myocarditis in a 16yo, late gadolinium enhancement: https://pubmed.ncbi.nlm.nih.gov/34778788/

Myocarditis in a 17yoM following vaccination: https://pubmed.ncbi.nlm.nih.gov/35105392/

Myocarditis presenting with hyperechoic nodule in a 17yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35470603/

Myocarditis in a 17yo Japanese male following Moderna: https://pubmed.ncbi.nlm.nih.gov/35495897/

Myocarditis in a 18yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34804729/

2 cases of myocarditis presenting with ST segment elevation in adolescent males after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34180390/

5 cases of myocarditis after Pfizer (age 16 and up): https://pubmed.ncbi.nlm.nih.gov/34092429/

5 cases of myocarditis, age 12-16, following Pfizer: https://pubmed.ncbi.nlm.nih.gov/36061387/

Follow-up cardiac magnetic resonance in 7 children with Pfizer vaccine associated myocarditis (80% with persistent abnormalities at 90 days): https://pubmed.ncbi.nlm.nih.gov/35482094/

5 cases of covid-19 vaccine induced myocarditis in 5 teenagers, a case series with further follow-up:https://pubmed.ncbi.nlm.nih.gov/35329143/

7 cases of myocarditis after mRNA vaccination (age 16 and up): https://pubmed.ncbi.nlm.nih.gov/35479661/

13 cases of Myocarditis in adolescents following Pfizer: https://www.jpeds.com/article/S0022-3476(21)00665-X/fulltext

Myocarditis in children following Pfizer: a case series (15 patients): https://pubmed.ncbi.nlm.nih.gov/34374740/

Review of 40 published case reports of myocarditis following covid vaccination (includes adolescents): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887934/

Review of 40 cases of myocarditis adolescents in South Korea following covid-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35626870/

A systematic review of 53 case reports of myocarditis, age range 14-80: https://pubmed.ncbi.nlm.nih.gov/35782472/

Review of 75 cases of myocarditis in Australia, age 12-17:  https://pubmed.ncbi.nlm.nih.gov/36053607/

Myocarditis in adolescents and adults following vaccination in 2021, review of 238 cases:https://pubmed.ncbi.nlm.nih.gov/35449353/

Myocarditis/myopericarditis in 269 individuals, a population based Danish cohort study (age 12 and above):https://pubmed.ncbi.nlm.nih.gov/34916207/

1077 cases of myocarditis and 1149 pericarditis following vaccination in Nordic residents, a cohort study (age 12 and up): https://pubmed.ncbi.nlm.nih.gov/35442390/

1626 cases of myocarditis in VAERS from Dec 2020-augut 2021, a review (JAMA (includes adolescents):https://pubmed.ncbi.nlm.nih.gov/35076665/

4 cases of myocarditis after 3rd dose of Pfizer: magnetic resonance imaging study (18-44yo): https://pubmed.ncbi.nlm.nih.gov/35310989/

8 cases of acute cardiac side effects after mRNA vaccination (age 13 and up): https://pubmed.ncbi.nlm.nih.gov/35655235/

Followup CMR imaging in 15 patients 6 months after Pfizer associated myocarditis (age 14-19): https://pubmed.ncbi.nlm.nih.gov/35320390/

14yoF with acute pancreatitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35081801/

17yoM with acute pancreatitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35053654/

A case of hepatotoxicity in 14yoF after receiving Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/35070524/

Liver injury and cytopenia in an adolescent following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35510521/

De Novo Pediatric Ulcerative Colitis trigger by Pfizer: a tale of 2 sistershttps://pubmed.ncbi.nlm.nih.gov/35762665/

Minimal change disease and acute interstitial nephritis in a 14yoM following Pfizer:https://pubmed.ncbi.nlm.nih.gov/35132446/

Minimal change disease in a 16yoM following 2nd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35586388/

Minimal change disease in a 18yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35611026/

16yoM with rhabdomyolysis following 2nd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35991822/

Uncommon side effects of COVID-19 vaccination in pediatrics, review of Delaware state data of 111 reports: https://pubmed.ncbi.nlm.nih.gov/36258808/

Thrombocytopenia in a teen with sickle cell disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34331506/

Pulmonary embolus and DVT in a 14yoM after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35173114/

Hemophagocytic lymphohistiocytosis (HLH) in a 14yoF requiring VA ECMO:https://pubmed.ncbi.nlm.nih.gov/35455321/

11yoF with HSP following 1st dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/36056360/

3 cases of adolescents with Pfizer induced TTP: https://pubmed.ncbi.nlm.nih.gov/35373880/

Severe refractory warm autoimmune hemolytic anemia after Pfizer in a teenage male managed with emergency splenectomy and complement inhibition with eculizumab: https://pubmed.ncbi.nlm.nih.gov/36107725/

Eosinophilic cellulitis following Pfizer in a 12yoM: https://pubmed.ncbi.nlm.nih.gov/35522122/

New-onset of vitiligo in a child following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35224170/

13yoF with adenomesenteritis following 1st dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35883977/

Vitiligo in a Ulcerative Colitis Patient following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34498300/

Bacillus Calmette-Guerin scar erythema in a 14yoF post Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/35175660/

9 cases of alopecia areata after covid vaccination (includes a 15 and 16yo patient):https://pubmed.ncbi.nlm.nih.gov/34931171/

Delayed cutaneous adverse reaction to AstraZeneca in a breastfed female infant: coincidence or rare effect?:https://pubmed.ncbi.nlm.nih.gov/35455352/

4 cases of oral erythema multiforme after Pfizer (includes 15yoM): https://pubmed.ncbi.nlm.nih.gov/35331228/

Herpes Zoster after Covid-19 vaccination in an adolescenthttps://pubmed.ncbi.nlm.nih.gov/36259868/

15yoF with pityriasis rosea following 2nd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/36004038/

Erythema Nodosum in a 17yoF following 2nd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35308066/

Toxic epidermal necrolysis (TEN) in a 12yoF after 1st dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/36000937/

Cutaneous adverse reactions following Pfizer, 20 cases, age 16 and uphttps://pubmed.ncbi.nlm.nih.gov/35607272/

Acute-onset dacryoadenitis in a 14yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35256374/

Acute Posterior multifocal placoid pigment epitheliopathy after Pfizer in a 17yoM: https://pubmed.ncbi.nlm.nih.gov/35412479/

3 cases of orbital inflammation after Pfizer and Moderna (13yoM included): https://pubmed.ncbi.nlm.nih.gov/35323144/

Bilateral retinal vasculitis and vitritis in two adolescents following covid-19 vaccination:https://pubmed.ncbi.nlm.nih.gov/36228169/

Retinal venous occlusion in a 13yoM following Corbevax COVID-19 vaccination:https://pubmed.ncbi.nlm.nih.gov/36190080/

Bilateral multifocal choroiditis with disc edema in a 15yoF following COVID-19 vaccination (Covaxin): https://pubmed.ncbi.nlm.nih.gov/36018135/

MIS-V in a teenage female: https://pubmed.ncbi.nlm.nih.gov/35354564/

MIS in a 9yoM and 14yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35891300/

Multisystem inflammatory syndrome in a 12yo male following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34978781/

Multisystem inflammatory Syndrome in a 12 year old boy after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34955518/

MIS in a 12yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35062704/

Two cases of MIS-V: 12yoM and 14yoM: https://pubmed.ncbi.nlm.nih.gov/35614536/

Two cases of MIS-V: 15yoF and 17yoF: https://pubmed.ncbi.nlm.nih.gov/35275051/

MIS in a 16yoM following 1st dose mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/35187466/

MIS-V in a 16yoM 3weeks after booster vaccination: https://pubmed.ncbi.nlm.nih.gov/35617041/

MIS-V in a 17yoM after his second dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34617315/

Multisystem inflammatory syndrome in children by covid-19 vaccination of adolescents in France: https://pubmed.ncbi.nlm.nih.gov/34928295/

Multisystem inflammatory syndrome in a COVID-19 vaccinated adolescent female with sickle cell disease: https://pubmed.ncbi.nlm.nih.gov/34955521/

Autoantibody release in children after COVID mRNA vaccination: A risk factor of multisystem inflammatory syndrome? https://pubmed.ncbi.nlm.nih.gov/34835284/

CDC MIS in children following vaccination: https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(22)00028-1/fulltext

Vulvar aphthous ulcer after Pfizer in a 12yoF: https://pubmed.ncbi.nlm.nih.gov/34888935/

Vulvar aphthous ulcer in a 14yoF after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34718079/

Vulvar aphthous ulcer in a 15yoF after 1st dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35930388/

Vulvar aphthous ulcer in a 16yoF after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34706274/

2 cases of adolescents with vulvar ulcers following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35104637/

Acute genital ulceration after Pfizer (12 and 14yo) and a 29yo after Moderna: https://pubmed.ncbi.nlm.nih.gov/35413297/

IgA nephropathy in a 12yoM after 1st dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35339305/

IgA nephropathy presenting as rapidly progressive glomerulonephritis in a 13yo following 1st dose of Pfizer:]https://pubmed.ncbi.nlm.nih.gov/34786589/

2 cases of IgA nephropathy patients with macroscopic hematuria after receiving the Pfizer vaccine, 13yoM and 17yo:https://pubmed.ncbi.nlm.nih.gov/34237324/

Sibling cases of IgA nephropathy (15yoM and 18yoM) following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35729514/

17yoM with newly diagnosed IgA nephropathy with gross hematuria following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34865167/

IgA nephropathy in a 13yoF and 16yoM following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35352188/

17yoF with IgA nephropathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35118635/

IgA nephropathy in 2 pediatric patients after Pfizer (13 and 17yo): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256683/

2 cases of macroscopic hematuria in children with IgA nephropathy remission following Pfizer (15yoF, 16yoF): https://pubmed.ncbi.nlm.nih.gov/35301586/

Relapse of idiopathic nephrotic syndrome following COVID-19 vaccination in a 17yoF: https://pubmed.ncbi.nlm.nih.gov/35416332/

Idiopathic nephrotic syndrome relapse following covid-19 vaccination, a series of 25 cases, age 16 and up:https://pubmed.ncbi.nlm.nih.gov/35979142/

Crescentic Glomerulonephritis, ANCA negative, in a 16yoF following 2nd dose Pfizer:https://pubmed.ncbi.nlm.nih.gov/35854121/

Two adolescent cases of acute tubulointerstitial nephritis after 2nd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35385678/

 

5 cases of POTS following vaccination, age 17 and up: https://pubmed.ncbi.nlm.nih.gov/35870086/

400+ Child Death Reports in VAERS?

As discussed, 32 children aged 0-17 died from COVID-19 in 2022. Source: CDC data tracker. According to the CDC VAERS system, 167 children aged 0-17 died from the COVID-19 vaccine. Upon further analysis, we believe the child deaths reported in VAERS may be upwards of 400+. A large quantity of VAERS reports, including death reports, do not have an age range designated. Unspecified death reports reviewed have identified hundreds of adolescent deaths that are not included in the automatic search for age. Find  examples below. Additional reports can be found on the VAERS website, or for easier search via the National Vaccine Information Center at medalerts.org, or via the VAERS dashboard. Analysis to identify additional reports done by Albert Benavides.

Support Community

Do you have a child suffering? Connect with our exclusive support forum for parents by contacting us.

Additional Resources

Want to learn more? Here are some top reads on the topic.

Science Magazine: Heart risks, data gaps fuel debate over COVID-19 boosters for young people. Risk of heart inflammation is small but new studies suggest it may take months to fully recover.

CDC.gov: Hospitalization rates are trending to lowest levels since pandemic monitoring began. 

A FAIR Health White Paper: Risk Factors for COVID-19 Mortality among Privately Insured Patients..000003% IFR for kids. High likelihood that comorbidities play a role.

Age-stratified infection fatality rate of COVID-19 in the non-elderly informed from pre-vaccination national seroprevalence studies. IFR was 0.0003% for age 0-19 years.